Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Pharmacoeconomics - Open
|
February 9, 2023
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
Esra Çakar, César Oniangue-Ndza, Ralph P Schneider, et al.
Pharmacoeconomics - Open
|
March 10, 2023
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
Shanlian Hu, Zhiliu Tang, James P Harrison, et al.
Advanced Healthcare Materials
|
November 28, 2012
Functionalized poly(γ-Glutamic Acid) fibrous scaffolds for tissue engineering
Cristina Gentilini, Yixiang Dong, Jessica R May, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 12, 2022
A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma
Shannon Cope, Keith Chan, Harlan Campbell, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 26, 2018
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
Rohit Mistry, Jessica R May, Gaurav Suri, et al.
Journal of Comparative Effectiveness Research
|
July 11, 2023
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma
Svenja Petersohn, Bradley McGregor, Sven L Klijn, et al.
Current Medical Research and Opinion
|
July 24, 2018
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer
Rohit Mistry, Gaurav Suri, Kate Young, et al.
Journal of Medical Economics
|
August 26, 2023
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective
Nishit Dhanji, Tassia Cristina Decimoni, Matthew T D Dyer, et al.
European Urology Oncology
|
February 26, 2023
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Pharmacoeconomics - Open
|
February 9, 2023
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
Esra Çakar, César Oniangue-Ndza, Ralph P Schneider, et al.
Pharmacoeconomics - Open
|
March 10, 2023
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
Shanlian Hu, Zhiliu Tang, James P Harrison, et al.
Advanced Healthcare Materials
|
November 28, 2012
Functionalized poly(γ-Glutamic Acid) fibrous scaffolds for tissue engineering
Cristina Gentilini, Yixiang Dong, Jessica R May, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 12, 2022
A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma
Shannon Cope, Keith Chan, Harlan Campbell, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 26, 2018
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
Rohit Mistry, Jessica R May, Gaurav Suri, et al.
Journal of Comparative Effectiveness Research
|
July 11, 2023
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma
Svenja Petersohn, Bradley McGregor, Sven L Klijn, et al.
Current Medical Research and Opinion
|
July 24, 2018
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer
Rohit Mistry, Gaurav Suri, Kate Young, et al.
Journal of Medical Economics
|
August 26, 2023
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective
Nishit Dhanji, Tassia Cristina Decimoni, Matthew T D Dyer, et al.
European Urology Oncology
|
February 26, 2023
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Page
of 1